

Section A1

Applicant

Annex Point II A1

1.1 Applicant

This dossier is submitted as a joint dossier.

The co-operating companies are Microbial Control (Switzerland) GmbH and ICL-IP Europe B.V. which details are provided below.

Name: **Microbial Control (Switzerland) GmbH**

Address: Wolleraustrasse 15-17, CH-8807 Freienbach, Switzerland

[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]

[REDACTED]
[REDACTED]
[REDACTED]

Name: ICL Europe Coöperatief U.A

[REDACTED]

Address: Prinsenhof Building
Koningin Wilhelminaplein 30
1062 KR Amsterdam
The Netherlands

[REDACTED]
[REDACTED]
[REDACTED]

1.2 Manufacturer of Active Substance

Please refer to the information provided in the Confidential Sections


1.3 Manufacturer of [REDACTED] Product(s) (if different)

Please refer to the information provided in the Confidential Sections

Section A2 Identity of Active Substance

Subsection
(Annex Point)

Official
use only

2.1	Common name (IIA2.1)	DBNPA Dibromonitrilopropionamide 2,2-Dibromo-3-nitrilopropionamide 2,2-Dibromo-2-cyanoacetamide
2.2	Chemical name (IIA2.2)	2,2-Dibromo-2-cyanoacetamide
2.3	Manufacturer's development code number(s) (IIA2.3)	none
2.4	CAS No and EC numbers (IIA2.4)	--
2.4.1	CAS-No	10222-01-2
2.4.2	EC-No	233-539-7
2.4.3	Other	--
2.5	Molecular and structural formula, molecular mass (IIA2.5)	--
2.5.1	Molecular formula	$C_3H_2Br_2N_2O$
2.5.2	Structural formula	
2.5.3	Molecular mass	241.9 g/mol
2.6	Method of manufacture of the active substance (IIA2.1)	Please see the confidential doc IIIA section 2 for information on the method of manufacture.
2.7	Specification of the purity of the active substance, as appropriate (IIA2.7)	Please see the confidential doc IIIA section 2

Section A2

Identity of Active Substance

2.8 Identity of impurities and additives, as appropriate (IIA2.8)	Please see the confidential data in IIA section 2 for information on the impurities.
2.8.1 Isomeric composition	There are no isomers
2.9 The origin of the natural active substance or the precursor(s) of the active substance (IIA2.9)	Not applicable: DBNPA and its precursors are no natural substances.

Section A2.10 Exposure data in conformity with Annex VIIA to Council
Directive 92/32/EEC (OJ No L, 05.06.1992,
Annex Point IIA2.10 p. 1) amending Council Directive 67/548/EEC

Subsection

Official
use only

2.10.1 Human exposure towards active substance

--

2.10.1.1 Production

[REDACTED]

2.10.1.2 Intended use(s)

--

1. Professional Users

For details please refer to Document IIB, Chapter 8.1.

i) Description of application process

For details please refer to Document IIB, Chapter 8.2.

ii) Workplace description

For details please refer to Document IIB, Chapter 8.2.

iii) Inhalation exposure

For details please refer to Document IIB, Chapter 8.2.

iv) Dermal exposure

For details please refer to Document IIB, Chapter 8.2.

2. Non-professional Users including the general public

DBNPA containing biocidal products are not intended to be used by non-professionals. However, secondary exposure to the general public is possible as people may come into contact with DBNPA treated materials.

Please also refer to the confidential versions of this section A2.10.1.2.

(i) via inhalational contact

Inhalation exposure is unlikely as DBNPA has a very low vapour pressure. For details please refer to Document IIB, Chapter 8.2.

(ii) via skin contact

Dermal exposure during the application of DBNPA and the handling of treated products performed by professionals can be considered to constitute a worst case. Please also refer to the assessment of secondary dermal exposure to DBNPA provided in the exposure assessments in Document IIB, Chapter 8.2.

(iii) via drinking water

Exposure of the general public to DBNPA via drinking water is not relevant for PT6

(iv) via food

Indirect exposure of the general public to DBNPA via food contact has been addressed in Doc IIB Section 8.2.5.

(v) indirect via environment

Indirect exposure of the general public to DBNPA via the environment is negligible. Please refer to Document IIA, Chapter 4 for details on the fate and distribution of DBNPA in the environment and Document IIB, Chapter 8.3 for environmental exposure assessments.

2.10.2 Environmental exposure towards

--

Document IIIA, Section A2

Section A2.10
Annex Point IIA2.10

Exposure data in conformity with Annex VIIA to Council
Directive 92/32/EEC (OJ No L, 05.06.1992,
p. 1) amending Council Directive 67/548/EEC

active substance

2.10.2.1 Production

[REDACTED]

2.10.2.2 Intended use(s)

--

Affected

compartment(s):

water

sediment

air

soil

Predicted

concentration in the

affected

compartment(s)

water

sediment

air

soil

For details please refer to Document IIB, Chapter 8.3.

For details please refer to Document IIB, Chapter 8.3.

For details please refer to Document IIB, Chapter 8.3.

For details please refer to Document IIB, Chapter 8.3.

For details please refer to Document IIB, Chapter 8.3.

For details please refer to Document IIB, Chapter 8.3.

For details please refer to Document IIB, Chapter 8.3.

For details please refer to Document IIB, Chapter 8.3.

For details please refer to Document IIB, Chapter 8.3.

For details please refer to Document IIB, Chapter 8.3.

Section A2.10
Annex Point IIA2.10

Exposure data in conformity with Annex VIIA to Council
Directive 92/32/EEC (OJ No L, 05.06.1992,
p. 1) amending Council Directive 67/548/EEC

Evaluation by Competent Authorities	
Use separate "evaluation boxes" to provide transparency as to the comments and views submitted	
EVALUATION BY RAPPORTEUR MEMBER STATE	
Date	<i>Give date of action</i>
Materials and methods	<i>State if the applicants version is acceptable or indicate relevant discrepancies referring to the (sub) heading numbers and to applicant's summary and conclusion.</i>
Conclusion	<i>Adopt applicant's version or include revised version</i>
Reliability	<i>Based on the assessment of the method include appropriate reliability indicator</i>
Acceptability	<i>acceptable / not acceptable (give reasons if necessary, e.g. if a study is acceptable despite a poor reliability indicator). Discuss the relevance of deficiencies.</i>
Remarks	
COMMENTS FROM ...	
Date	<i>Give date of comments submitted</i>
Results and discussion	<i>Discuss additional relevant discrepancies referring to the (sub)heading numbers and to applicant's summary and conclusion. Discuss if deviating from view of rapporteur member state</i>
Conclusion	<i>Discuss if deviating from view of rapporteur member state</i>
Reliability	<i>Discuss if deviating from view of rapporteur member state</i>
Acceptability	<i>Discuss if deviating from view of rapporteur member state</i>
Remarks	